WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H407337
CAS#: 603101-22-0
Description: GNF-1331 is a Potent, Selective, and Orally Bioavailable Porcupine Inhibitor (IC50 = 12 nM). Blockade of aberrant Wnt signaling is an attractive therapeutic approach in multiple cancers. Wnt signaling is tightly controlled during cellular proliferation, differentiation, and embryonic morphogenesis. Aberrant activation of this pathway plays a critical role in a variety of cancers, such as cutaneous squamous cell carcinoma (SCC), breast cancer, and colorectal cancer.
Hodoodo Cat#: H407337
Name: GNF-1331
CAS#: 603101-22-0
Chemical Formula: C20H20N6O2S2
Exact Mass: 440.11
Molecular Weight: 440.540
Elemental Analysis: C, 54.53; H, 4.58; N, 19.08; O, 7.26; S, 14.55
Synonym: GNF-1331; GNF 1331; GNF1331.
IUPAC/Chemical Name: N-(6-methoxybenzo[d]thiazol-2-yl)-2-((4-propyl-5-(pyridin-4-yl)-4H-1,2,4-triazol-3-yl)thio)acetamide
InChi Key: JIUFLMSAFMXEEC-UHFFFAOYSA-N
InChi Code: InChI=1S/C20H20N6O2S2/c1-3-10-26-18(13-6-8-21-9-7-13)24-25-20(26)29-12-17(27)23-19-22-15-5-4-14(28-2)11-16(15)30-19/h4-9,11H,3,10,12H2,1-2H3,(H,22,23,27)
SMILES Code: O=C(NC1=NC2=CC=C(OC)C=C2S1)CSC3=NN=C(C4=CC=NC=C4)N3CCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 440.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors
Dai Cheng, Jun Liu, Dong Han, Guobao Zhang, Wenqi Gao, Mindy H. Hsieh, Nicholas Ng, Shailaja Kasibhatla, Celin Tompkins, Jie Li, Auzon Steffy, Fangxian Sun, Chun Li, H. Martin Seidel, Jennifer L. Harris, and Shifeng Pan
Publication Date (Web): May 10, 2016 (Letter)
DOI: 10.1021/acsmedchemlett.6b00038
